Varicella Vaccine Market - By Vaccine Type, By Application, By Age Group, By Procurement – Global Forecast, 2025 - 2034

Varicella Vaccine Market Size

The global varicella vaccine market was valued at USD 3.4 billion in 2024. The market is expected to grow from USD 3.5 billion in 2025 to USD 6.3 billion in 2034, at a CAGR of 6.5% during the forecast period. The high global burden of varicella (chickenpox) is a key factor driving the growth of this market.
 

For instance, as per an article published in the BMJ Journal, varicella-zoster virus (VZV) affects an estimated 84 million cases annually. This growing burden of varicella majorly stems from the increasing global pediatric population and the corresponding emphasis on childhood immunization. For instance, as per UNICEF, in 2023, the population of children aged below 18 years was estimated to be around 2,415 million worldwide. Thus, this growing pediatric population further creates a sustainable need for varicella vaccines to protect against virus.

In addition, technological advancements have further fueled the growth of the global varicella vaccine market. The development of combination vaccines such as mumps, measles, rubella, and varicella (MMRV) has improved compliance to immunization by reducing the number of injections required. Further, the growing government initiatives and funding supporting immunization programs are accelerating the growth of this market.
 

Moreover, the rising incidence of the varicella-zoster virus in densely populated regions further supports the growth of this market. For instance, varicella (chickenpox) is a serious public health problem in China, with the most reported cases among childhood vaccine-preventable infectious diseases, and its reported incidence has increased over 20-fold in the last decade. Such growing prevalence of this highly contagious infection increases the demand for vaccines, thereby boosting the market growth.
 

Varicella vaccine is a live attenuated vaccine which protects an individual from varicella-zoster virus (VZV) responsible for chickenpox. It includes a weakened version of this virus which triggers the immune system to frame protective measures against the virus without going through the full disease process.
 

Varicella Vaccine Market Trends

• The increased prevalence of chickenpox is a primary factor supporting the growth of the varicella vaccines market.
   
• Chickenpox caused by VZV is a highly infectious disease that can easily spread among children, especially in crowded places and in communities where vaccination is not available. Even though such diseases can be controlled with vaccines, several countries continue to suffer from a high burden of disease due to low vaccination rates or a lack of a comprehensive immunization program.
   
• Moreover, as stated by World Health Organization (WHO), in several populations, before vaccines became widely available, chickenpox affected nearly 90% of individuals by the age of 15. Countries without national immunization programs still report 8 to 10 million new cases annually. These figures highlight the need for expanded vaccine access, particularly in low-income and middle-income regions.
   
• Another significant trend driving the growth of the global market is the rapid advancement in vaccine technology, resulting in improved safety and efficacy of varicella vaccines.
   
• The development of monovalent and combination vaccines such as MMRV provides flexibility in immunizing different populations. Such innovations offer long-term protection and prevent the incidence of chickenpox.
   
• With the growing awareness about disease and the rapid development of healthcare infrastructure in emerging markets, the increased trend in immunization programs will continue to drive the demand for these vaccines.
   

Varicella Vaccine Market Analysis

In 2021, the global market was valued at USD 3 billion and experienced growth to reach USD 3.1 billion in 2022 and USD 3.2 billion in 2023.
 

Based on the vaccine type, the global market is segmented into monovalent varicella vaccine and combination varicella vaccine. The monovalent varicella vaccine segment dominated the market and was valued at USD 2.2 billion in 2024.
 

• The dominance of this segment is primarily driven by its widespread adoption in national immunization programs, particularly in developing countries with low-income.
   
• These vaccines are cost-effective, easily procured in bulk, and require simple logistics compared to combination vaccines. Owing to these advantages, the monovalent varicella vaccine segment is expected to witness high growth in the coming years.
   
• Additionally, their long-standing use in routine childhood immunizations, supported by both public and private organizations, has reinforced their position in the global market.
   
• These vaccines have been in use for many years with a well-established efficacy and proven safety records. This has built trust and familiarity among healthcare providers and policymakers, thereby driving the adoption and growth of these vaccines.
   

Based on the application, the global varicella vaccine market is classified into chickenpox immunization and mumps, measles, rubella, and varicella (MMRV) immunization. The chickenpox immunization segment held highest market share of 59.9% in 2024.
 

• The chickenpox segment dominates the market owing to its widespread occurrence and high immunization demand, especially in children.
   
• Many national immunization programs have made childhood chickenpox vaccinations compulsory or strongly recommended them, resulting in a significant increase in uptake of monovalent varicella vaccines.
   
• The high transmission rate of the varicella-zoster virus (VZV), which causes chickenpox, further emphasizes the need for widespread vaccination, ensuring consistent demand for varicella vaccines globally.
   
• Moreover, developed nations with advanced healthcare systems and universal vaccination programs are key contributors to this high market share. Emerging markets are also catching up driven by awareness, better healthcare access, and government initiatives aimed at incorporating the chickenpox vaccine into the national immunization schedule.
   

Based on the age group, the global varicella vaccine market is categorized into pediatrics and adolescents and adults. The pediatrics segment is expected to grow at a significant CAGR of 6.6% during the forecast timeframe.
 

• The inclusion of varicella vaccination in national childhood immunization schedules in many countries drives the growth of this segment. The mandatory pediatric vaccination, including chickenpox immunization is strongly recommended during the first few years of life, which ensures consistent and large-scale demand for these vaccines in children.
   
• Further, chickenpox significantly affects children and is a primary childhood disease mainly occurring in children under 10 – 15 years of age. This epidemiology drives the focus on early immunization in children, thereby solidifying the leading position of the pediatric segment in the market.
   
• Moreover, the increasing awareness among parents about the benefits of childhood vaccination and government initiatives is contribute to the higher uptake of pediatric vaccines globally.
   

Based on the procurement, the global varicella vaccine market is divided into public and private. The public segment dominated in 2024 and is anticipated to reach USD 4.3 billion by 2034.
 

• The growth of this segment is attributed to the extensive reach and structured implementation of government-led immunization programs.
   
• Many countries, particularly those with established healthcare systems, have integrated varicella vaccination into their National Immunization Programs (NIPs), enabling large-scale vaccine deployment through public health infrastructure.
   
• These programs often prioritize early childhood immunizations, which aligns with the epidemiology of varicella, as the majority of infections occur in children.
   
• Further, the ability of governments to procure vaccines in bulk through centralized tenders and pooled purchasing systems significantly increases the market share of the public segment.
   
• With growing awareness of varicella's health and economic implications, governments have shown stronger policy commitments toward prevention through public funding. This has translated into sustained investments and regular programmatic reviews to ensure high-impact vaccine delivery, thereby further strengthening the market share of the public segment.
   

The North America varicella vaccine market dominated the global market with a market share of 39.1% in 2024.
 

• The favorable government authorities such as FDA and Health Canada have supported the approval and wide adoption and commercial availability of varicella vaccines, which enabled early market entry and continued availability.
   
• In addition, North America has one of the highest health insurance coverage rates globally, covering the varicella vaccination for individual recipients, reducing out-of-pocket costs for individuals, thus increasing adoption of these vaccines in the region.
   

The U.S. varicella vaccine market was valued at USD 1.07 billion and USD 1.11 billion in 2021 and 2022, respectively. The market size reached USD 1.21 billion in 2024, growing from USD 1.16 billion in 2023.
 

• The growth in the U.S. market stems from the strong national varicella immunization campaign, which has minimized the incidence of the disease as well as the healthcare burden for the last twenty years.
   
• For instance, as per the Centers for Disease Control and Prevention (CDC), annual cases of chickenpox in the U.S. have declined to fewer than 150,000, with under 1,400 hospitalizations and fewer than 30 deaths per year. These significant reductions highlight the effectiveness of the widespread vaccination strategies in enhancing public health outcomes.
   
• Moreover, the U.S. Food and Drug Administration (FDA)’s supportive regulatory environment expedites the approval and commercialization of vaccines, fostering growth and reinforcing the country’s market position.
   

Europe varicella vaccine market accounted for USD 974.3 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Urbanization and improved healthcare access in the European countries are supporting pediatric immunization infrastructure, leading to high demand for routine vaccine among infants and young children.
   
• Further, strong partnerships between health ministries, pharmaceutical companies, and academic institutions are facilitating improved vaccine access, education, and adoption throughout the region, thus fostering market growth.
   

Germany varicella vaccine market is anticipated to witness considerable growth over the analysis period.
 

• The country benefits from an efficient healthcare delivery system, with widespread access to pediatric and general practitioners who play a key role in administering vaccines and maintaining high immunization coverage.
   
• Germany's advanced biotech and pharmaceutical sectors contribute to vaccine innovation, efficient manufacturing, and secure supply chains, supporting uninterrupted access to high-quality varicella vaccines.
   

The Asia Pacific varicella vaccine market is anticipated to grow at the highest CAGR of 7% during the analysis timeframe.
 

• This growth is fueled by a combination of factors, including a large and growing pediatric population, increasing awareness of vaccine-preventable diseases, and rising healthcare investments by regional governments.
   
• Many countries in the region, such as India, China, Japan, and South Korea, are scaling up their national immunization programs to include varicella vaccines, supported by improved cold chain logistics and healthcare infrastructure.
   
• Urbanization and economic development have improved access to pediatric care and preventive health services, contributing to rising vaccine uptake.
   

China varicella vaccine market is predicted to grow significantly over the forecast period.
 

• China holds a dominant position in the Asia Pacific market, largely due to its vast population base and government-driven immunization initiatives.
   
• The country's national immunization program includes varicella vaccination, which has led to widespread coverage across urban and semi-urban areas.
   
• Another key factor driving China's leadership in this market is its robust vaccine manufacturing infrastructure.
   
• The presence of major domestic vaccine producers such as Sinovac and Changchun Changsheng Life Sciences enables the country to meet large-scale domestic needs while also supplying to neighboring countries.
   
• The ability to manufacture vaccines at scale and lower costs gives China a competitive edge, making varicella vaccines more accessible and affordable across different regions within the country.
   

Brazil is expected to experience significant growth in the Latin America varicella vaccine market over the coming years.
 

• The Brazilian Ministry of Health has included varicella vaccination as part of the National Immunization Program (PNI), ensuring free access through the public healthcare system. This policy has led to high coverage, particularly in the pediatric population.
   
• Furthermore, Brazil has one of the largest public healthcare systems in the world, SUS (Sistema Único de Saúde), which allows for widespread vaccine distribution even in remote areas.
   

Saudi Arabia varicella vaccine market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The market is set to grow substantially, driven by the government's long-term healthcare transformation strategy under Vision 2030.
   
• As part of this initiative, the Kingdom is investing heavily in expanding preventive healthcare services and integrating vaccines more widely into routine immunization programs. Varicella vaccination is strongly recommended for school and daycare admission, ensuring high coverage among children.
   
• Public health campaigns led by the Ministry of Health continue to raise awareness about the importance of vaccination in preventing complications of chickenpox.
   

Varicella Vaccine Market Share

The global market is characterized by a consolidated competitive landscape, with a few major players dominating the market. The top 5 players, including Merck, GlaxoSmithKline, Sanofi, GC Pharma, and Bio-Med, account for approximately 55% of the market share. These companies leverage extensive research and development capabilities, robust distribution networks, and strategic partnerships to maintain their market positions. As the demand for universal immunization grows, competition is expected to intensify, leading to broader access, affordability, and innovation across the varicella vaccine space.

Varicella Vaccine Market Companies

Few of the prominent players operating in the varicella vaccine industry include:

• Bio-Med
• Changchun Changsheng Life Sciences Limited
• GC Pharma (Green Cross Holdings)
• GlaxoSmithKline
• Merck
• Mitsubishi Tanabe Pharma Corporation
• Novo Medi Sciences
• Sanofi
• Seqirus
• Sinovac Biotech
• SK Bioscience
• Takeda Pharmaceutical Company Limited
   
• Merck has strengthened its position in the global market through the WHO pre-qualification of its VARIVAX (varicella virus vaccine live) in June 2018. This recognition confirms the vaccine’s safety, efficacy, and manufacturing quality, allowing it to be procured by international health organizations. With this approval, VARIVAX gained broader access to low- and middle-income countries, helping expand global immunization efforts. WHO endorsement not only supports Merck’s role in disease prevention but also enhances its global distribution footprint and trust among healthcare systems worldwide.
   
• Bio Pox by Bio-Med is indicated for active immunization against varicella virus (chickenpox) in healthy individuals with no prior history of infection and susceptible healthy close contacts. The vaccine complies with the stringent standards of the Indian Pharmacopoeia, ensuring high quality and safety. Additionally, Bio-Med’s manufacturing facilities adhere to current Good Manufacturing Practices (cGMP) as per the revised Schedule ‘M’ of the Drugs and Cosmetics Act, Government of India. This strong regulatory compliance and commitment to quality manufacturing position Bio-Med as a reliable player in the market.
   

Varicella Vaccine Industry News

• In January 2025, to mark National Girl Child Day, Novo Medi Sciences (Novo Group), in collaboration with 150 pediatricians across 15+ cities and with support from CRY (Child Rights and You), launched an initiative to vaccinate 300 underprivileged girls in India against chickenpox. The campaign promotes vaccine awareness and girl child health empowerment. This effort enhanced Novo’s social impact and strengthened its brand presence in community healthcare.
   
• In June 2024, Sinovac Biotech announced that its varicella vaccine, PROVARIX (Vero Cell, Live), received approval from China’s National Medical Products Administration (NMPA) for use in adolescents and adults aged 13 and above. The approved immunization follows a two-dose schedule with a 4 to 8-week interval. Previously, PROVARIX was authorized only for children aged 12 months to 12 years. This expanded approval strengthened Sinovac’s market presence by broadening its target population and increasing potential vaccine demand.
   
• In March 2023, Merck announced FDA approval for the addition of intramuscular (IM) administration to the U.S. Product Insert (USPI) for its MMRV vaccines—M-M-R II, VARIVAX, and ProQuad. This approval enhanced administration flexibility, potentially improving provider convenience and expanding vaccine uptake across various healthcare settings.
   

The varicella vaccine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Monovalent varicella vaccine
• Combination varicella vaccine

Market, By Application

• Chickenpox immunization
• Mumps, measles, rubella, and varicella (MMRV) immunization

Market, By Age Group

• Pediatrics
• Adolescents and adults

Market, By Procurement

• Public
• Private

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE